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The aim of the study was to improve cytogenetic diagnostics and monitoring of myelofibrosis and to reveal the spectrum of cytoge-
netic abnormalities in patients from Ukraine. Materials and Methods: A total of 42 patients (23 females and 19 males) with myelo-
fibrosis was studied using different cytogenetic methods. Granulocyte colony-stimulating factor (G-CSF) was added by the new 
method during cultivation of peripheral blood (PB) cells from 31 patients for specific stimulation of mitotic divisions. Two patients 
underwent examination by fluorescent in situ hybridization method. Results: In cell cultures of PB stimulated in vitro with G-CSF 
and in non-stimulated bone marrow chromosome abnormalities were found in 19 (45.2%) of all the patients. The spectrum of cy-
togenetic abnormalities of bone marrow and PB was the same in all of the patients. Aspiration of bone marrow was unsuccessful 
due to significant fibrosis in 10 (29.4%) of 34 patients. The study by fluorescent in situ hybridization method confirmed cytoge-
netic abnormalities revealed by G-method and discovered additional possibly normal subclone. Conclusions: Cytogenetic study 
of PB using in vitro G-CSF as a specific stimulant of mitosis instead of phytohemagglutinin revealed significant variety of chro-
mosomal abnormalities in Ukrainian patients with myelofibrosis. This method could be a less invasive alternative to cytogenetic 
examination of bone marrow in the subgroup of patients with considerable fibrosis and consecutive changes. The usage of fluores-
cent in situ hybridization method supplemented karyotyping by G-banding method.
Key Words: myelofibrosis, karyotype, peripheral blood, granulocyte colony-stimulating factor, G-banding, fluorescent in situ 
hybridization.
Myelofibrosis (MF) as a myeloproliferative neo-
plasm (MPN) could be either idiopathic (primary) 
or arise due to transformation of such MPNs as poly-
cythemia vera and essential thrombocythemia. Cy-
togenetic studies are often crucial for diagnosis 
of MF according to modern WHO criteria [1], because 
this requires myeloproliferative changes to be con-
firmed by clonality markers. Molecular genetic studies 
give additional opportunities for such confirmation, but 
they require the usage of expensive and complicated 
sequencing methods in large amount of the patients. 
Cytogenetic study of metaphase chromosomes using 
G-method of differential staining could allow revea-
ling the spectrum of cytogenetic abnormalities of all 
chromosomes of the cell, including rare changes ap-
pearing in the small subclones of pathological cells. 
Searching for such rare abnormalities is particu-
larly challenging at low mitotic activity of pathological 
cells and with insufficient quantity of substrate for 
analysis that often accompanies MF [2]. Appearance 
of cytogenetic abnormalities and their accumulation 
could change patient’s prognostic risk according 
to dynamic international prognostic scoring system 
(DIPSS) and require to adjust treatment regimen [3]. 
Currently, the “golden standard” in MF diagnostics 
is cytogenetic investigation of bone marrow (BM). 
However, aspiration of BM is often unsuccessful 
in MF, because of considerable fibrotic changes and 
replacement of hemopoietic cell clusters onto reticulin 
and collagen fibers. In this case, repeated punctures 
of the BM are needed. These manipulations are quite 
uncomfortable for patients, and even sometimes after 
several repeats may be ineffective [4]. In the 80th the 
cytogenetic analysis of peripheral blood (PB) instead 
of BM was proposed [5]. However, standard methods 
of PB examination using phytohemagglutinin (PHA) 
lead to stimulation of lymphoid cells that usually are not 
affected in MF. On the other hand, cytogenetic studies 
of blood without stimulant in most cases cannot pro-
vide sufficient mitotic activity to conduct the analysis 
of metaphase chromosomes in the sample [6]. Fluo-
rescent in situ hybridization (FISH) method can be ap-
plied for the detection of cytogenetic abnormalities 
in MF. The method has higher sensitivity to certain ab-
normalities of chromosomes than routine karyotyping 
with G-method. Effectiveness of FISH studies is shown 
for the diagnostics of myelodysplastic syndromes [7]. 
However, this high-precision method cannot unveil 
the whole spectrum of changes in cells’ karyotype 
without the usage of very expensive multiplex FISH 
approach [8]. An important feature of FISH method 
is the ability to detect abnormalities in interphase cells, 
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unlike the G-method of differential staining that reveals 
abnormalities in mitotically active cells.
Thus, the methods of cytogenetic analysis 
in MF should be improved in sensitivity to small patho-
logical cell subclones, as well as become more suitable 
for larger amount of patients, and should require less 
painful manipulation at diagnosis and during monito-
ring of the disease.
The aim of the study was to improve cytogenetic di-
agnostics and monitoring of MF and to reveal spectrum 
of cytogenetic abnormalities in Ukrainian patients.
MATERIALS AND METHODS
A total of 42 patients (23 females and 19 males) 
with MF were studied. The average age of the patients 
in the study was about 57 years (56.3 years in males and 
57.6 in females). 38 patients suffered from idiopathic 
(primary) MF and in 4 patients secondary MF was diag-
nosed (3 patients had transformation of polycythemia 
vera to MF, and in 1 patient MF evolved from essential 
thrombocythemia). Patients were residents of 8 regions 
of Ukraine: Lviv, Ternopil, Ivano-Frankivsk, Khmelnitsky, 
Volyn, Vinnytsia, Rivne and Zakarpattya.
Patients were examined according to the protocol 
of medical care approved by the Ministry of Health 
of Ukraine. For the study the following laboratory 
methods were used: complete blood count with cyto-
logical examination of blood smears stained with May-
Grünwald — Giemsa staining; iliac trephine biopsy 
with subsequent histological examination of biopsy 
samples. If the diagnosis was doubtful, immunohis-
tochemical study was performed.
Cytogenetic methods were used. BM aspirate 
in vitro cultivation followed by subsequent cytogenetic 
analysis were performed for 25 patients (9 males and 
16 females). BM samples were prepared by standard 
method [9] without stimulation. Cytogenetic analysis 
of PB was performed for 31 patients (15 males and 
16 females) with immature myeloid progenitor cells 
in blood smears. Three different methods were used for 
cultivation of PB. In order to specifically stimulate mitotic 
division of circulating stem cells, blast cells and other im-
mature myeloid precursors of PB the granulocyte colony-
stimulating factor (G-CSF) filgrastim (Dr. Reddy’s, India) 
was added during cell cultivation for the cytogenetic 
blood samples of all 31 patients (patent of Ukraine ap-
plication № a201505498 from 04.06.2015). 10 patients 
(5 males and 5 females) among these 31 were selected 
for a control group. PB for this group was also cultivated 
with 2 other methods: without any stimulation and with 
addition of PHA (Gibco, USA) [10]. In 12 patients (5 males 
and 7 females) cytogenetic study was performed for 
both PB and BM. Also 10 patients underwent cytogenetic 
reexamination of the PB with G-CSF stimulation from 
6 to 12 months after the initial examination.
In all cases in vitro 24 hours cultivation with RPMI 
1640 culture medium and fetal calf serum was per-
formed. To stop mitosis at metaphase colchicine 
solution was used. Cells were fixed by standard me-
thods. G-Method of differential staining of metaphase 
chromosomes was used. Cytogenetic analysis was 
performed with light microscope at magnification 
10×100 using recommendations of ISCN [11, 12].
Before the collection of the samples for cytoge-
netical study the patients were recommended to stop 
any cytotoxic therapy, i.e. hydroxyurea or interferon-
alpha for the period of 3 to 7 days in order to maintain 
cell proliferation and to avoid distortion of the results 
of cytogenetic analysis.
To confirm and clarify cytogenetic abnormalities 
in 2 patients additional studies of interphase PB cells 
by FISH method were carried out after using G-banding 
method of differential staining. For one of them the study 
by FISH method was repeated after 12 months, and for 
another patient also interphase nuclei of cells in BM were 
examined. The mixture of FISH probes for centromeric 
regions of chromosome 3 (D3Z1) and 9 (D9Z1) were used: 
CEP3 (Spectrum Orange), CEP9 (Spectrum Aqua), (Ab-
bott, USA). For centromeric regions and long arms of chro-
mosome 8 (D8Z2 and TRPS1) the mixture of FISH probes 
CEP8 (Spectrum Aqua) and LSI8q23.3 (Spectrum Red) 
(Cytosell, UK). For subsequent loci of chromosome 5, 
such as 5p15.2 (CTNND2), 5p15.31 (FLJ25076) and 
5q35 (SOTOS) — a mixture of probes LSI5p15.2 (Spec-
trum Red), LSI5p15.31 (Spectrum Green), LSI5q35 (Spec-
trum Green) (Cytosell, UK) were used.
The study received permission of the local ethics 
committee and was conducted according to the prin-
ciples of the Helsinki Declaration of Human Rights, 
the European Convention on Human Rights and 
Biomedicine, and the laws of Ukraine. All the patients 
subscribed informed consent for the participation 
in the study. However, 8 patients refused to undergo 
BM puncture, so, the cytogenetic investigation 
of BM wasn’t performed for these 8 patients.
RESULTS AND DISCUSSION
Cytogenetic analysis of PB samples without 
stimulation of cell division was unsuccessful in all 
10 patients of control group due to either insufficient 
quantity and quality of metaphase plates or lack 
of mitosis in the samples. If PHA was used to stimulate 
lymphocytes in venous blood, normal karyotype was 
revealed in every patient of this control group, because 
lymphoid cells in MF were theoretically unaffected 
by the disease, as expected. However, in cell cultures 
of PB leukocytes stimulated in vitro with G-CSF and 
in non-stimulated BM samples chromosome abnor-
malities were detected in 19 (45.2%) of all the patients. 
In 23 (54.8%) of patients normal karyotype was found. 
The results of the cytogenetic study of the cells ob-
tained from G-CSF-stimulated PB and non-stimulated 
BM in patients with MF are presented in the Table.
Chromosome abnormalities were detected in 9 male 
patients and 10 females. Among patients with cyto-
genetic abnormalities only one clonal abnormality 
of karyotype was revealed in 10 patients (52.6%). Two 
chromosomal abnormalities were observed in 3 patients 
(15.8%). 6 patients (31.6%) with cytogenetic abnor-
malities had initially complex karyotype. Abnormalities 
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of chromosome 9 were the most common, and were 
observed in 6 patients (31.6% of patients with karyotype 
changes), and in 4 of them monosomy of chromosome 
9 was detected.
Table. Spectrum of cytogenetic abnormalities in patients with MF
No.
Gen-
der/Age 
(years)
Ma-
teri-
al
Karyotype
1 М/59 BM 46,XY[12]/47,XY,+8[2]/93,XXYY[2]/4n±[1]
2 M/27 PB 46,XY[16]/46,XY,del5p12[2]/46,XY,del9q21q32[1]/ 
46,XY,der15[1]/4n±[1]
BM 46,XY[16]/46,XY,del5p12[1]/46,XY,der(15)/
[1]/46,XY,del9q21q32[1]/4n±[2]
3 M/59 BM 50,XY,+1,+2,+19,+mar1[7]/
/59,XY,idem,+6,+8,+9,+11,+20,+21,+22,+mar2,
+mar3[2]
4 F/41 PB 46,XX[13]/47,XX,+8[3]
BM 46,XX[5]/47,XX,+8[2]
5 F/60 BM 46,XX[14]/47,XX,+12[1]/3n±[2]/4n±[4]
6 F/54 BM 46,XX[15]/4n±[3]
7 F/67 PB 49,ХХ,+3,+8,+9[16]/48,XX,+3,+9[1]/46,XX[1]
PB* 49,ХХ,+3,+8,+9[19]/46,XX[1]
BM 49,XX,+3,+8,+9[8]
8 F/52 PB 46,XX[4]/44,XX,-5,-17[2]/45,XX,-17[2]
PB* 46,XX[1]/46,XX,i(17q)[10]
BM 46,XX[4]/43,XX,-5,-17,-18[3]/44,XX,-5, -17[3]/45,XX,-17[4]
9 M/54 PB 46,XY,14ph+[5]/45,XY,14ph+,-7[3]
PB* 46,XY,14ph+[10]/44,XY,14ph+,-7,-9[2]/4n±[1]
10 F/65 PB 47,XX,del(5)(q12->qter),+der(9)t(5;9)(5qter-
>5q12::9p?->9qter),+mar,-9[8]
PB* 47,XX,del(5)(q12->qter),+der(9)t(5;9)
(5qter->5q12::9p?->9qter),+mar,-9[5]/ 
/45,XX,idem,-13,-15[4]
11 М/69 PB 44,XY,+rea(1),+8,+mar,-3,-5,-7,-15,-17[5]/
/39,XY,idem,-2,-6,-11,-19,-21[1]
12 F/72 PB 46,XX[14]4n±[2]
PB* 46,XX[18]/45,XX,-22[3]
13 M/60 PB 46,XY[11]/47,XY,+rea(1)[2]
14 M/34 PB 46,XY[11]/44,XY,-15,-Y[2]/45,XY,-Y[1]
15 M/62 PB 46,XY[12]/45,XY,-3[2]/43,XY,idem,-9,-21[1]
16 F/48 PB 46,XX [5]/45,XX,-7[3]
BM 46,XY[1]/45,XY,-7[3]
17 F/59 PB 46,XX[10]/46,XX,20q-[3]/44,XX,idem,-17,-22[2]
18 F/69 PB 47,XX,+2,+13,-7[5]/45,XX,+idem,-7,-8,-21[1]
BM 47,XX,+2,+13,-7[3]
19 M/35 PB 46,XY[6]/45,XY,-7[3]
BM 46,XY[1]/45,XY,-7[3]
Note: M — male; F — female; PB — peripheral blood; BM — bone marrow; 
PB* — cytogenetic reexamination of peripheral blood.
Trisomies were diagnosed in 7 patients (36.8%). 
Among frequently detected trisomies there were ad-
ditional copies of chromosomes 1–3, 6, 8, 9, 11–13 and 
19. Trisomy of chromosome 8 was the most commonly 
revealed, being found in 4 patients. Among other ab-
normalities frequently noted in the literature, the dele-
tion 20q11 was identified in only one patient as a small 
subclone. According to molecular genetic studies this 
abnormality could be present in lower percentage 
of PB cells comparing to BM cells [13]. BM collection for 
cytogenetic study was not always possible in our study, 
and PB studies were performed instead. This could 
be an explanation of the rarity of this abnormality. False-
negative results could also appear due to difficulties 
in detection of small deletions of 20q using G-method.
In patients with MF structural rearrangements were 
presented by deletions, inversions and translocations 
involving long and short arms of chromosomes 1, 5, 9, 
17, and 20. Complex translocations were found in 6 pa-
tients, and 2 of them had 2 or more additional abnormal 
chromosomes appeared as a result of translocations. 
Also, in some patients fractures in centromere regions 
of chromosome 9 were revealed.
In 1 patient (sample No. 11 in the Table) with a com-
plex karyotype presented by additional co pies of chromo-
some 8, chromosome 1 derivatives and other rearrange-
ments, abnormal mitosis with complete fragmentation 
of chromosomes was revealed. This phenomenon is as-
sumed as a biomarker of mitotic cell death and elimina-
tion of genetically unstable cells. It was established that 
the more severe morphological anaplasia of tumors and 
the higher mitotic activity of cells is, the more common 
abnormal mitosis occur [14].
The rearrangements considered as prognosti-
cally unfavorable according to IPSS/DIPSS Plus were 
observed in 9 patients (47.4% among patients with 
abnormalities of chromosomes). Hypodiploid clonal 
karyotype was revealed in 4 patients. The most frequent 
were losses of chromosomes 7 and 9, and monosomy 
of chromosome 5 was slightly more rare. Besides 
complex karyotype, trisomy of chromosome 8 and 
monosomy of chromosomes 5 and 7, other unfavo-
rable cytogenetic abnormalities were revealed, such 
as del(5)(q12.1-qter) and isochromosome i(17q).
In patients with MF cell clones with increased ploidy 
to 3n± and more frequently 4n± (samples No. 2, 5, 6, 
12 in the Table) were detected. Polyploid cells were 
identified in 5 patients, and 4 of them had a combina-
tion with other chromosome abnormalities.
Polyploidy was a notable feature of the cells 
in patients with MF, because it implied copy number 
increase of mutated genes. Such changes could cause 
the appearance of clonal benefits through enhanced 
ability to proliferate and could lead to higher genetic 
instability through greater chance of chromosomes’ 
abnormal disjunction during mitosis followed by sig-
nificant quantitative changes of chromosomes.
In all patients with detected chromosomal abnorma-
lities the mosaic karyotype with the number of cell 
clones from 2 to 4 (mostly both abnormal and normal) 
was observed. Only in 2 (5%) patients no cellular 
subclones with normal karyotype were detected. This 
implied genetic heterogeneity of the hematopoietic 
cells and the possibility of subclone detection using 
 G-method of cytogenetic analysis in this disease. This 
also could confirm the coexistence of normal and patho-
logical hematopoiesis in almost all patients with MF.
So, we could speculate about the potential of this 
disease to be curable in case of effective elimination 
of abnormal cells during the treatment process without 
allogenic hemopoietic stem cells transplantation, since 
high proportion of patients with cytogenetically normal 
subclones has been revealed.
Aspiration of BM was unsuccessful due to signifi-
cant fibrosis in 10 (29.4%) of 34 patients which agreed 
to undergo BM puncture. In 3 cases (2 cases for the 
study of BM and 1 case for G-CSF-stimulated PB) 
karyotyping was unsuccessful due to lack of meta-
phase plates in the samples (low mitotic rates). 
So, the results of both PB and BM simultaneous 
cytogenetic analysis were accessible in only 12 pa-
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tients. There were no cases where cytogenetic study 
of BM showed abnormal karyotype along with normal 
karyotype of G-CSF stimulated PB, and vice versa. 
The spectrum of cytogenetic abnormalities of BM and 
PB was the same in all the patients. However, in some 
patients the quantity of the cells in exact cellular clones 
was diffe rent. In case of such quantity differences 
in polyploid cell clones a possible explanation is the 
presence of an increased number of megakaryocyte 
precursors able to became polyploid in BM.
To reduce the quantity of invasive diagnostic pro-
cedures, such as repeated BM punctures, cytogenetic 
reexamination of the patients was performed using 
G-CSF stimulated PB from 6 to 12 months after initial 
examination. 3 (30%) of a total of 10 patients with 
cytogenetic reexamination performed had new clonal 
findings in the karyotypes (No. 8, 10, 12 in the Table). 
Such clonal abnormalities as i(17q), monosomies 
of chromosomes 13, 15, and 22 were revealed in these 
patients. In one another case, patient’s abnormal com-
plex karyotype remained unchanged after 6 months 
of observation (No. 7 in the Table). The clinical condi-
tion of all these 4 patients had been exacerbating with 
worsening of anemia, splenomegaly and weakness. 
Two of them died in 6 months after reexamination. 
In other patients with no clonal chromosomal abnor-
malities at the initial cytogenetic examination, no new 
clonal karyotype abnormalities were revealed.
For both 2 patients whom the study with FISH probes 
was made, the cytogenetic findings revealed by G-me-
thod in BM and G-CSF stimulated PB were confirmed. 
The study by FISH method revealed the same trisomies 
of chromosomes both in BM and in G-CSF-stimulated 
PB of the patient No. 7 (see the Table). Below is a brief 
description of another case with confirmation of the 
origin of the marker chromosomes using FISH-method.
Clinical example. 65 years old female patient with 
hepatosplenomegaly, portal hypertension, and severe 
anemia was diagnosed as idiopathic MF after histo-
logical examination of trephine biopsy material and 
molecular genetic evaluation of JAK2V617F mutation. 
Extensive reticulin and collagen fibrosis of BM along 
with the presence of the mutation in JAK2 gene 
were confirmed. Leukogram showed significant shift 
to myelocytes (18%), metamyelocytes (16%), and 
band neutrophils (10%). High concentration of im-
mature nucleated erythroid precursors (10 erythro-
karyocytes to 100 leukocytes) in the PB smear was 
revealed. The patient underwent periodical treatment 
with hydroxyurea. Repeated puncture of the sternum 
and iliac crest to aspirate BM failed, and therefore, 
it was not possible to conduct cytogenetic studies 
using standard techniques. The cytogenetic study 
of PB by culturing cells in vitro using G-CSF was 
performed instead. The mitotic index of PB cells was 
high enough to obtain metaphase plates for karyoty-
ping. As a result of the study, the following karyotype 
was revealed: 47,XX,del(5)(q12->qter),+der(9)t(5;9)
(5qter->5q12::9p?->9qter),+mar,-9[8].
The involvement of short arms of chromosome 9, 
where JAK2 gene is situated, could possibly lead 
to additional activation of the mutated gene and give 
clonal advantage for the pathologically changed cells.
For the analysis of the patient’s PB cells’ interphase 
nuclei with FISH method the fluorochrome labels for 
short and long arms of chromosome 5 (Fig. 1) were 
used to detect cytogenetic abnormalities quantitatively 
and to prove the presence of deleted chromosome 
fragments and derivatives.
5p15.31 5q355p15.2
Fig. 1. Schematic view of chromosome 5 with loci 
5p15.31 (FLJ25076), 5p15.2 (CTNND2) and 5q35 (SOTOS) labeled 
by FISH method with a mixture of probes LSI5p15.31 (Spectrum 
Green), LSI5p15.2 (Spectrum Red) and LSI5q35 (Spectrum Green)
58 cell nuclei from 100 analysed showed 3 signals 
from short arms and 2 signals from long arms of chromo-
some 5 (Fig. 2, a). In other 38 cell nuclei normal count 
of 2 signals for both short and long arms of chromo-
some 5 were detected (Fig. 2, b). In 4 cells the only one 
signal from long arm and 2 signals from short arms were 
revealed (Fig. 2, c). As far as only 2 short and 2 long arms 
of chromosome 5 had been identified by cytogenetic 
analysis using G-method, it could be assumed that chro-
mosome 5 was involved to the formation of the marker 
chromosome in 58% of the PB cells, where three signals 
from the genetic material of chromosome’s 5 short arms 
were confirmed by FISH method.
ba c
Fig. 2. Nuclei of interphase cells of venous blood of the pa-
tient with abnormalities of chromosome 5 labeled by FISH 
method (magnification 10×100): a) 3 signals from short arms 
(combined red and green) and 2 signals from long arms (green 
only) of chromosome 5 (CTNND2x3,FLJ25076x3,SOTOSx2); 
b) normal count of 2 signals for both short (combined 
red and green) and long (green only) arms of chromo-
some 5 (CTNND2,FLJ25076,SOTOS)×2; c) 1 signal from the long 
arm (green only) and 2 signals from the short arms (combined red 
and green) of chromosome 5 (CTNND2x2,FLJ25076x2,SOTOSx1)
Cytological analysis of PB smears of the patient 
at the time of cytogenetic analysis revealed that 77.3% 
of leukocytes had myeloid origin, 13.6% of PB were 
from lymphoid lineage, and 9.1% were immature 
nucleated erythroid precursors. Thus, the number 
of the cells of non-myeloid origin that theoretically 
shouldn’t be affected in MF was significantly lower than 
the number of cells with normal quantity of fluorescent 
signals according to the study by FISH method. This 
could indicate the presence of a subclone of myeloid 
cells with normal karyotype undetected by G-banding 
cytogenetic analysis.
The reexamination after one year of observation 
to assess the dynamics of cytogenetic changes was 
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made also using in vitro G-CSF-stimulated PB. A total 
of 17 metaphase plates of satisfactory quality were 
obtained, and the following karyotype was revealed:
47 , X X , d e l ( 5 ) ( q 12 - > q t e r ) , + d e r ( 9 ) t ( 5 ; 9 )
( 5 q t e r - > 5 q 12 : : 9 p ? - > 9 q t e r ) , + m a r, - 9 [ 5 ] / 
/45,XX,idem,-13,-15[4].
Thus, clonal evolution of the cells with the appe-
arance of additional monosomy was detected along with 
the changes observed in the first examination. There-
fore, dynamic cytogenetic study of G-CSF stimulated 
PB could in this case provide confirmation of disease 
progression. The presence of all these chromosomal 
abnormalities could attribute the patient to high risk 
according to the DIPSS-Plus [3], though without these 
cytogenetic data, she was assigned to the intermedi-
ate-2 risk group. The patient’s clinical condition was 
consistent with high risk group, as predicted by cyto-
genetics, while being deteriorated during observation. 
She became dependent from transfusions of red blood 
cell concentrate. Weakness, spleen and liver volumes 
progressively increased, 1–2% of blast cells and promy-
elocytes appeared in PB leukocyte count in 6 months, 
despite active therapy. Neither erythropoietins followed 
by thalidomide + prednisolone could relieve anemia, nor 
further use of interferon-alpha could influence hepato-
splenomegaly and PB changes. Thus, the application 
of our method of cytogenetic investigation with G-CSF 
stimulation allowed in this case to obtain more informa-
tion of potentially important diagnostic and prognostic 
value. Application of FISH method of PB examination 
after G-banding allowed to determine anomalies that 
are difficult to detect using differential staining of meta-
phase chromosomes. FISH method increased sensiti-
vity of cell subclones detection.
In conclusion, cytogenetic investigation of PB and 
BM in MF revealed a significant variety of chromosomal 
abnormalities in patients from Ukraine. Cytogenetic 
studies of PB using in vitro specific stimulant G-CSF 
instead of PHA in this disease may be a good alterna-
tive to cytogenetic examination of BM in the subgroup 
of patients with prominent fibrosis and consecutive 
changes. PB studies reduce the need of painful in-
vasive diagnostic manipulations and facilitate follow-
up of the patients.
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